Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.265 AUD | -2.32% | +0.80% | +25.87% |
Mar. 25 | Miners, healthcare firms push Australia stocks higher | RE |
Mar. 21 | Morgans Financial Downgrades Sigma Healthcare to Hold From Add; Price Target is AU$1.14 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company shows low valuation levels, with an enterprise value at 0.4 times its sales.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 30.83 and 25.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.87% | 1.32B | B- | ||
+16.62% | 70.95B | C+ | ||
+2.99% | 25.25B | C+ | ||
+5.38% | 8.67B | C | ||
+6.46% | 8.16B | B | ||
-21.01% | 7.91B | B- | ||
-0.18% | 4.51B | B- | ||
+17.12% | 4.31B | B+ | ||
-0.14% | 4.07B | B- | ||
-3.64% | 3.84B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SIG Stock
- Ratings Sigma Healthcare Limited